1. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation, 2006. Available at: http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf
2. Saad M.F., Lillioja S., Nyomba B.L. et al. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med. 1991;324(11):733-9.
3. Diabetes and Obesity: Time to Act. International Diabetes Federation (IDF) and International Association for the Study of Obesity (IASO), 2004.
4. Brunzell J.D., Ayyobu A.F. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med. 2003;115 Suppl 8A:24S-28S..
5. Robins S.J., Rubins H.B., Faas F.H. et al. Insulin resistance and cardiovascular events with low HDL cho�lesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;26(5):1513-7.
6. Steinmetz A., Fenselau S., Schrezenmeir J. Treatment of dyslipoproteinemia in the metabolic syndrome. Exp Clin Endocrinol Diabetes 2001:109(4):S548-59.
7. Lindstrom J., Louheranta A., Mannelin M. et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003;26:3230-6.
8. Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361: 2005-16.
9. Haffner S.M., Alexander C.M., Cook T.J. et al. Reduced coronary events in simvaststin-treated patients with coronary heart disease and diabetes mellitus or impaired fasting glucose level: subgroup analysis on the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159(22):2661-7.
10. Chobanian A.V., Bakris G.L., Black H.R. et al. Seventh repot of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42(6): 1206-52.
11. Knowler W.C., Barrett-Connor E., Fowler S.E. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6):393-403.
12. Durbin R.J. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab. 2004;6(4):280-5.
13. Chiasson J.L., Josse R.G., Comis R. et al. Stop-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP�NIDDM trial. JAMA 2003;290(4):486-94.
14. Torgerson J.S., Hauptman J., Boldrin M.N., Sjöström L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. A randomised study of orlistat as an adjunct to lifestyle changes for the preventionof type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.
